Tandem duplication of the FLT3 gene in acute lymphoblastic leukemia: a marker for the monitoring of minimal residual disease TO 
THE EDITOR
Fms-like tyrosine kinase 3 (FLT3), also referred as to FLK2 or STK-1, is a member of the class III receptor tyrosine kinase (RTK) family, along with KIT, FMS and PDGFR. Binding of its natural ligand induces FLT3 dimerization and consecutive tyrosine kinase activation and autophosphorylation. This signal transduction cascade plays an important role in growth control of pluripotent hematopoietic cells, early progenitor cells and immature lymphocytes. The structure of FLT3 is composed of five immunoglobulin-like subdomains in the extracellular region, a single transmembrane (TM) and a juxtamembrane (JM) domain, two intracellular tyrosine kinase domains (TK1 and TK2) separated by a kinase insert domain and a C-terminal domain.
An internal tandem duplication of the FLT3 gene (FLT3/ITD) has been discovered in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) with frequencies of 20% and 3-15%, respectively. 1, 2 The FLT3/ITD is restricted to the JM/TK1 domains corresponding to exon 11-12 and is occasionally accompanied by the insertion of a few nucleotides. The FLT3/ITD is a somatic event since no 1 The function of FLT3/ITD has not been fully elucidated. A recent study demonstrated that elongation of the JM domain causes ligand-independent dimerization of the mutant FLT3 receptor, resulting in a constitutive activation. 3 The authors assumed that a DNA-replication error could generate FLT3/ITD. Apart from AML patients, Xu et al 4 reported on an FLT3/ITD in two ALL patients. We therefore searched for FLT3/ITD upon polymerase chain reaction (PCR) analysis in 174 children with ALL. Moreover, we describe that FLT3/ITD can be used as marker for the detection of minimal residual disease (MRD).
DNA samples obtained from 174 children with ALL were randomly selected for this study after informed consent was obtained. All patients were enrolled in the German MRD study of the multicenter trial BFM 90. 5 The immunophenotypes comprised 11 pre-pre-B ALLs, 110 common ALLs, 28 pre-B ALLs and 25 T-ALLs. High molecular weight DNA was extracted from the bone marrow aspirates at initial presentation using a standard method. Buffy coat (BC) was collected from five healthy volunteers.
Genomic DNA was amplified to detect FLT3/ITD at the JM/TK1 domains using primers 11F and 11R. 1 One hundred ng of leukemic DNA was amplified by PCR in a total volume of 50 l with 1× PCR buffer, 1 U of Taq polymerase recombinant (Life Technologies, Karlsruhe, Germany), 200 M of each deoxyribonucleotide triphosphate (dNTP) (DNA polimerization mix; Amersham Pharmacia Biotech, Freiburg, Germany), 1.5 mM MgCl 2 , and 40 pmol of each primer. The PCR mixture was initially heated for 4 min at 94°C, followed by amplification (40 cycles) with 30 s at 94°C, 45 s at 50°C, and 45 s at 72°C and a final elongation step of 10 min at 72°C on a thermal cycler (Primus96; MWG Biotech, Ebersberg, Germany). PCR products were electrophoresed with a 100 bp size marker (Amersham Pharmacia Biotech) on a 3% agarose gel (FMC, Rockland, ME, USA) containing ethidium bromide. FLT3/ITD was characterized by cloning of the PCR fragment into a plasmid vector (TOPO TA cloning kit, Invitrogen, Groningen, The Netherlands). Sequencing reactions were carried out using a Cy5 Thermo Sequenase Dye Termination Kit (Amersham Pharmacia Biotech) and analyzed on an autosequencer (ALFexpress II; Amersham Pharmacia Biotech). Ten-fold serial dilutions of initial leukemic DNA into BC DNA were performed in the range from 10 −1 to 10
. One microgram of each dilution step and BC DNA were amplified in a 100 l PCR reaction containing 1× PCR buffer, 1 U of Taq polymerase recombinant (Life Technologies), 200 M of each dNTP, 2 mM MgCl 2 , 40 pmol of 11F, 40 pmol of 11R (first-round PCR). The PCR condition was the same as the screening step described above. For the following second-round PCR step, 6 l of the first PCR product were diluted in 294 l of 5 mM Tris-HCl, 0.5 mM EDTA, pH 8.0. For the patient harboring FLT3/ITD, an allelle-specific oligonucleotide (ASO) corresponding to the junction between the duplicated regions was designed.
Among the 174 ALL patients, only one common ALL patient (0.6%) showed an aberrant 364 bp PCR product in addition to the 133 bp wild-type product upon amplification with the primers 11F and 11R. 1 Sequence analysis revealed that in this case a 198 bp region derived from exon/intron 11 and the first 22 bp of exon 12 was duplicated and also contained a 11 bp insertion (Figure 1a) . The deduced amino acid sequence at the duplicated region is shown in Figure 1b . Four tyrosine residues, ie Y589, Y591, Y597 and Y599 were involved in this duplication. Recently, Xu et al 4 reported that two (3.3%) out of 60 childhood ALL patients showed FLT3/ITD. The leukemia cells of one ALL patient expressed CD5, CD7, CD11b and CD33 but not CD10, CD19 or HLA-DR. In another ALL patient leukemia cells expressed CD13, CD19, CD34 and HLA-DR, but not CD10. They concluded that FLT3/ITD occurs partly in lymphoid lineage cells with the potential of myeloid differentiation. In contrast, the common ALL patient reported here did not exhibit coexpression of myeloid marker (CD13 1%, CD33 7%). Therefore, FLT3/ITD can occur in ALL patients, albeit rarely.
We next used this molecular marker for the detection of MRD and designed a mutation-specific primer (82ASO, 5Ј-CAT CTC CTC GTC GCG GGC AC-3Ј) in addition to a new primer for exon 11 of FLT3 (11F3Ј, 5Ј-TGG TAC AGGT GAC CGG CTC C-3Ј) (Figure 1c ). We firstly amplified 1 g DNA of each dilution step and BC using primers 11F and 11R (first-round PCR). In this step, all samples but water showed a 133 bp wild-type FLT3. A mutation-specific fragment (364 bp) was observed at dilution steps of 10 −1 to 10
. Two microliters of diluted first-round PCR were amplified under the conditions described above with 40 pmol of primers 11F-3Ј and 82ASO. The amplification process consisted of 30 cycles of 30 s at 94°C, 30 s at 60°C, and 45 s at 72°C and a final elongation step of 5 min at 72°C. In the second-round PCR using primers 11F-3Ј and 82ASO, the detection limit of the leukemia-specific 233 bp fragment was determined as 10 −4 (Figure 1d ). Two bone marrow follow-up samples obtained 15 months and 18 months after diagnosis, respectively, were available from this patient. Our analysis did not reveal any evidence of residual leukemia (Figure 1d) . The MRD statue of this patient had been previously analyzed by two clone-specific V␦2-D␦3 markers. 5 The results obtained by both methods match.
The clinical significance of FLT3/IDT has been evaluated in childhood and adult AML patients. 6, 7 Both studies revealed a significantly shorter survival in AML patients with FLT3/ITD than in AML patients with wild-type FLT3. Hence, with respect to AML, FLT3/ITD serves as a relevant genetic alteration predicting an adverse prognosis, irrespective of age. On the other hand, two ALL patients with FLT3/ITD reported previously 4 survived for 44 and 72 months. Our ALL patient with FLT3/ITD showed no evidence of MRD 3 years after diagnosis. Therefore, ALL with FLT3/ITD may not be associated with a poor prognosis, although the very low incidence of this molecular alteration in ALL currently prevents a definite conclusion. More importantly, we describe the FLT3/ITD as a novel marker for the detection of MRD. In FLT3/ITDs, an unique sequence emerges at the junction of the two repeated sequences. Hence, an allele-specific primer can be designed even if no insertion occurs between the duplicated sequences. This method could become a helpful tool for the monitoring of MRD in patients harboring FLT3/ITD, particularly in AML patients.
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Comments on a published paper: Abe 'Infantile Leukemia and Soybeans'
TO THE EDITOR I was surprised to read the editorial by T Abe on infant acute leukaemia in Leukemia. 1 Abe suggests that genistein, a topoisomerase II inhibitor, which occurs abundantly in soybeans, may be largely responsible for the development of infant acute leukemia. Although he has provided evidence that genistein can induce chromatid-type chromosomal aberrations, the epidemiological evidence is clearly against an association between genistein ingestion and infant leukemia. As stated, the incidence of infant acute leukaemia in Japan is comparable to that in other countries in which large amounts of soybean products are not consumed. To keep his hypothesis viable Abe proposed an unsubstantiatable post-hoc modification, which suggests that Japanese infants are protected from the putative harmful effects of genistein by favourable genetic polymorphisms. Overall I felt that the hypothesis was undeveloped and I believe that Abe and Leukemia were premature in printing his ideas. At the very least the final dogmatic sentence of his abstract should have been modified.
As we all know, however the progress of science relies on the generation of new ideas, and perhaps the publication of such hypotheses may generate some more useful ideas and discussion. The issue however is more complex. Since the biomedical literature is frequently misquoted, I predict that in the future the literature will cite Abe's article as if it was based on some 'truth', and entrench the concept that genistein has a role in the onset of infant leukaemia. We all generate numerous hypotheses, mostly poorly defined and perhaps irrational, occasionally useful. But, before we publish any or each of these ideas we must provide logical, convincing and biologically plausible arguments, or even better, concrete experimental or epidemiological evidence, in support of our hypotheses.
